OXM effects seen in obese patients with and without T2DM; comparable effects to liraglutide in T2DM
WEDNESDAY, March 21, 2018 (HealthDay News) — In obese subjects with and without type 2 diabetes mellitus (T2DM), oxyntomodulin (OXM) significantly augments glucose-dependent insulin secretion, according to a study published online March 15 in Diabetes.
Sudha S. Shankar, M.D., from Merck & Co. Inc. in Kenilworth, N.J., and colleagues examined the effects of OXM on glucose homeostasis. The effects of an intravenous infusion of native OXM on insulin secretory rates (ISR) and glycemic excursion were assessed in a graded glucose infusion (GGI) procedure in two separate placebo-controlled trials in 12 overweight and obese subjects without diabetes and in 12 obese subjects with T2DM. The glucagon-like peptide-1 (GLP-1) analog liraglutide was a comparator in the T2DM trial.
The researchers found that in the GGI, 3.0 pmol/kg/min of OXM significantly increased ISR in both groups and blunted glycemic excursion relative to placebo. The effects of OXM were comparable to those of liraglutide among individuals with T2DM, including the restoration of beta cell glucose responsiveness to that of non-obese subjects without diabetes.
“Our findings indicate that native OXM significantly augments glucose-dependent insulin secretion acutely in obese subjects with and without diabetes, with effects comparable to pharmacologic GLP-1 receptor activation and independent of weight loss,” the authors write. “Native OXM has potential to improve hyperglycemia via complementary and independent induction of insulin secretion and weight loss.”
Several authors disclosed financial ties to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
Copyright © 2018 HealthDay. All rights reserved.
